Tags : Issues

The US FDA Issues Final Guidance on Interchangeable Biosimilars

Shots: The US FDA finalizes its guidance on interchangeability of a biosimilar with its reference biologic, which means it may be substituted without prescriber intervening The final guidance provides clarity to the developers that the proposed biological product should meet the interchangeability standard under the Public Health Service Act (PHS Act) Till date, the US […]Read More